Procainamide–Cisplatin in Pregnant Mice

2026-08-31

The 2006 reference study evaluated whether procainamide hydrochloride could accompany cisplatin in pregnant mice without worsening embryotoxicity. Its key finding was that combination treatment did not increase adverse developmental effects and modestly improved selected fetal endpoints, possibly through reduced fetal cisplatin exposure and protection of the dam.

Rottlerin PKC Inhibitor: Workflow & Assays

2026-08-30

Rottlerin supports concentration- and time-resolved studies of PKCδ-linked proliferation and apoptosis, while its barrier effects create a useful cautionary model for endothelial assays. This workflow combines pathway readouts with nanoparticle uptake principles from a recent ocular drug-delivery study to improve experimental interpretation.

Chrysanthemum indicum Extract Against Glioma

2026-08-29

This pre-proof study integrates network pharmacology, molecular docking, and in vitro and in vivo experiments to investigate how Chrysanthemum indicum L. extract may act against glioma. Its findings connect extract-associated compounds with androgen receptor-centered signaling and show reduced C6-cell proliferation and migration alongside increased apoptosis.

Bazedoxifene A3232: Assay Design Guide

2026-08-29

This scenario-based guide explains how Bazedoxifene (SKU A3232) can support more interpretable cell viability, proliferation, and cytotoxicity workflows. It connects estrogen receptor biology, solvent handling, concentration design, data interpretation, and product-selection criteria to literature and product-documentation evidence.

Amikacin Sulfate: From Ribosome to Precision Therapy

2026-08-28

A translational perspective on Amikacin Sulfate that connects ribosomal bactericidal activity with intracellular delivery, granulomatous tissue exposure, assay design, safety strategy, and emerging antimicrobial peptide platforms.

Mucocutaneous Candidiasis: Evidence and Treatment

2026-08-28

The reference guideline integrates clinical morphology, direct microscopy, risk-factor assessment, and treatment selection for cutaneous and oral candidiasis. Its central practical contribution is showing why microscopy-confirmed infection, rather than culture positivity alone, should guide diagnosis and why correction of local and systemic predispositions is essential for preventing recurrence.

Separating Growth Inhibition from Cell Death in Cancer

2026-08-27

Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that anti-cancer treatments can suppress proliferation and induce cell death in different proportions and on different timelines. This framework supports more precise interpretation of in vitro drug-response experiments and helps researchers avoid treating a single viability value as a complete measure of drug action.

Alfuzosin HCl: BPH Assay & Formulation Workflows

2026-08-27

Build more reproducible benign prostatic hyperplasia research workflows with Alfuzosin HCl, from solution preparation and release testing to selective spectrophotometric quantification. The approach combines α1-adrenergic pharmacology with practical controls for overlapping spectra, short solution stability, and formulation-matrix interference.

NF 340: Turning P2Y11 Biology Into Translation

2026-08-26

NF 340 offers translational researchers a way to interrogate the P2Y11 node linking purinergic signaling, cytoskeletal remodeling, and breast cancer invasion. This article connects the QPRT–P2Y11–Rho/ROCK–PLC/MLCK axis to practical assay design, competitive positioning, and responsible expansion into immunology research and inflammation pathway modulation.

Promethazine HCl and Host-Directed Immunity

2026-08-26

Promethazine HCl is more than a histamine H1 receptor antagonist: it is a tractable phenothiazine scaffold for connecting histaminergic signaling, macrophage biology, ROS, autophagy, and translational host-directed therapy research. This article interprets recent phenothiazine evidence while outlining a disciplined strategy for evaluating promethazine hydrochloride across immunology, inflammation research, and neuroscience.

Naftifine HCl: A Framework for Mechanistic Assays

2026-08-25

Naftifine HCl is an allylamine antifungal agent for precise sterol-biosynthesis research. This article presents a differentiated assay framework that connects target-level pharmacology, fungal phenotypes, and lessons from WNT5a/GSK3/β-catenin pathway research without overstating cross-domain evidence.

Panobinostat (LBH589): Cancer Research Workflows

2026-08-25

Build reproducible HDAC inhibition studies with Panobinostat (LBH589), from acetylation and apoptosis readouts to drug-resistance models. A translational workflow also shows how this broad-spectrum HDAC inhibitor can be evaluated as a sensitizer for oncolytic herpes simplex virus in malignant meningioma models.

CCK-8 and Endogenous Opioid Control of Withdrawal Anxiety

2026-08-24

The 2014 Neuroscience study showed that centrally administered cholecystokinin octapeptide (CCK-8) reduced anxiety-like behavior in morphine-withdrawal rats through a CCK1 receptor- and endogenous opioid-dependent mechanism. Its pharmacological design distinguishes CCK-8 from anxiety-promoting CCK paradigms and identifies central CCK1 signaling as a candidate pathway for studying the negative affective component of opioid withdrawal.

Bazedoxifene Inhibits Malaria Parasites and Hemozoin

2026-08-23

MRSA Extracellular Vesicles and OSCC Proliferation

2026-08-22

A 2026 study reports that extracellular vesicles released by methicillin-resistant Staphylococcus aureus promote oral squamous cell carcinoma growth through an IL-8–CXCR1 signaling axis. By combining extracellular-vesicle characterization, pathway inhibition, genetic validation, and mouse tumor experiments, the work links antibiotic-resistant bacteria to tumor progression and identifies CXCR1 signaling as a mechanistically testable intervention point.